Iovance Biotherp Stock Price, News & Analysis

Iovance Biotherapeutics (NASDAQ: IOVA) announced the publication of five-year analysis results for Amtagvi (lifileucel) in the Journal of Clinical Oncology, showing significant durability in treating advanced melanoma. The Phase 2 C-144-01 trial, involving 153 patients, demonstrated an objective response rate of 31.4%, with median response time of 1.4 months and duration of 36.5 months. Nearly one-third of responders maintained ongoing responses at the five-year mark. The median overall survival was 13.9 months, with a five-year survival rate of 19.7%. Amtagvi, approved by FDA in February 2024, is the first one-time T cell therapy for solid tumors and the first approved treatment for advanced melanoma after anti-PD-1 and targeted therapy. The therapy showed no new or late-onset adverse events at median follow-up of 57.8 months.

Iovance Biotherapeutics announced five-year results from the Phase 2 C-144-01 trial of Amtagvi® (lifileucel) in advanced melanoma patients. The study included 153 patients previously treated with anti-PD-1 and targeted therapy. Key findings with a median follow-up of 57.8 months include:

• 19.7% five-year survival rate with median overall survival of 13.9 months
• 31.4% objective response rate (5.9% complete responses, 25.5% partial responses)
• 36.5-month median duration of response
• 31.3% of responders maintained ongoing responses at five years

Amtagvi, approved by FDA in February 2024, is the first one-time T cell therapy for solid tumor cancer. The therapy demonstrated a favorable long-term safety profile with no new or late-onset treatment-related adverse events.

Iovance Biotherapeutics (NASDAQ: IOVA), a biotechnology company specializing in TIL therapies for cancer patients, has granted inducement stock options to 59 new non-executive employees. The grants, approved on May 15, 2025, cover 278,770 shares of common stock with an exercise price of $1.76 per share. These options were awarded under the company's Amended and Restated 2021 Inducement Plan, following Nasdaq Listing Rule 5635(c)(4).

The stock options feature a three-year vesting schedule, with one-third vesting on the first employment anniversary and the remaining shares vesting quarterly over the following two years, contingent on continued employment.

[ "Expansion of workforce with 59 new employees indicates company growth", "Structured vesting schedule helps retain talent over a 3-year period", "Stock options align employee interests with company performance" ]

Iovance Biotherapeutics (IOVA) reported Q1 2025 financial results with total product revenue of $49.3M, including $43.6M from Amtagvi and $5.7M from Proleukin sales. The company revised its FY25 total product revenue guidance to $250M-$300M. First quarter revenue was impacted by scheduled maintenance at the Iovance Cell Therapy Center, but production has now resumed at full capacity. The company maintains $366M in cash and expects funding into 2H26. Iovance has treated over 275 Amtagvi patients and generated more than $210M in revenue in the first 12 months of U.S. launch. The company expects regulatory approvals for Amtagvi in the UK, EU, and Canada in 2025. Their network includes over 80 Authorized Treatment Centers (ATCs) across 35 states, with 48 centers having completed patient infusions. Manufacturing turnaround time is approximately 34 days, and reimbursement coverage extends to over 250 million lives.

Iovance Biotherapeutics (NASDAQ: IOVA), a biotech company specializing in novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for cancer patients, has scheduled its first quarter 2025 financial results and corporate updates webcast for Thursday, May 8, 2025, at 4:30 p.m. ET. The company's management will host a conference call and live audio webcast to discuss the quarterly results and provide business updates. Investors and interested parties can access the webcast through the company's website at IR.Iovance.com or by registering directly at the provided link. The webcast recording will remain available for one year after the event.

Iovance Biotherapeutics (NASDAQ: IOVA) has announced its participation in two major scientific conferences, showcasing significant developments in their TIL therapy pipeline. At the 2025 AACR Annual Meeting (April 25-30), the company will present pre-clinical data for IOV-5001, their novel genetically engineered IL-12 TIL cell therapy.

At the 2025 ASCO Annual Meeting (May 30-June 3), Iovance will present two key studies: five-year outcomes data from the C-144-01 study of lifileucel monotherapy in advanced melanoma patients, and a poster on lifileucel's study design for frontline advanced non-small cell lung cancer treatment.

The company will also host a panel discussion with melanoma experts on May 31, 2025, at 6 PM CDT, with both live and archived webcasts available on their website.

Iovance Biotherapeutics (NASDAQ: IOVA) has announced the approval of inducement stock options for new employees on April 17, 2025. The grants cover 297,600 shares of common stock, distributed among fifty new, non-executive employees. The options were issued under the company's Amended and Restated 2021 Inducement Plan, with an exercise price of $3.06 per share, matching the closing price on the grant date.

The stock options feature a three-year vesting schedule, with one-third vesting on the first employment anniversary and the remaining portions vesting in eight quarterly installments over the following two years, contingent on continued employment.

Iovance Biotherapeutics (NASDAQ: IOVA) has announced the approval of inducement stock options for new employees on March 20, 2025. The company granted options covering 308,710 shares of common stock to 43 new, non-executive employees under its Amended and Restated 2021 Inducement Plan.

The stock options were granted with an exercise price of $3.54, matching the closing price of Iovance's common stock on the grant date. The vesting schedule spans three years, with one-third of shares vesting on the first employment anniversary and the remaining shares vesting in eight quarterly installments over the following two years, contingent on continued employment.

Iovance Biotherapeutics (NASDAQ: IOVA) reported strong financial results for Q4 and FY2024. Total product revenue reached $73.7M in Q4 and $164.1M in FY24, hitting the upper end of guidance. The company's flagship product Amtagvi generated $48.7M in Q4 and $103.6M in FY24 revenue, while Proleukin contributed $25.0M in Q4 and $60.5M in FY24.

The company reaffirmed its FY25 revenue guidance of $450M-$475M and expects cash burn under $300M. With approximately $422M in cash as of February 2025, Iovance is funded into H2 2026. The company anticipates 2025 regulatory approvals for Amtagvi in the UK, EU, and Canada.

Q4 2024 net loss was $78.6M ($0.26/share), improved from $116.4M ($0.45/share) in Q4 2023. FY24 net loss was $372.2M ($1.28/share), better than $444.0M ($1.89/share) in FY23.